IC
Ikarian Capital Portfolio holdings
AUM
$302M
This Quarter Return
+12.69%
1 Year Return
+65.21%
3 Year Return
+441.33%
5 Year Return
+548.26%
10 Year Return
–
AUM
$269M
AUM Growth
+$269M
(-5%)
Cap. Flow
+$20.3M
Cap. Flow
% of AUM
7.54%
Top 10 Holdings %
Top 10 Hldgs %
54.13%
Holding
130
New
23
Increased
25
Reduced
23
Closed
23
Top Buys
| 1 |
Soleno Therapeutics
SLNO
|
$15.8M |
| 2 |
Rocket Pharmaceuticals
RCKT
|
$13.4M |
| 3 |
Immunovant
IMVT
|
$11.4M |
| 4 |
Akero Therapeutics
AKRO
|
$10.1M |
| 5 |
Crinetics Pharmaceuticals
CRNX
|
$9.45M |
Top Sells
| 1 |
Apellis Pharmaceuticals
APLS
|
$12.2M |
| 2 |
Merck
MRK
|
$11.5M |
| 3 |
Biohaven
BHVN
|
$8.36M |
| 4 |
Insmed
INSM
|
$8.34M |
| 5 |
IDEAYA Biosciences
IDYA
|
$7.39M |
Sector Composition
| 1 | Healthcare | 97.77% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Astria Therapeutics
ATXS
$394M
| $2.8M | 0.34% |
374,807
-204,583
| -35% | -$1.53M |
|
|
27
Biohaven
BHVN
$1.71B
| $2.76M | 0.33% |
106,138
-321,279
| -75% | -$8.36M |
|
28
Larimar Therapeutics
LRMR
$337M
| $2.7M | 0.32% |
+682,868
| New | +$2.7M |
|
29
Voyager Therapeutics
VYGR
$204M
| $2.37M | 0.29% |
305,857
+5,857
| +2% | +$45.4K |
|
30
InflaRx
IFRX
$117M
| $2.05M | 0.25% |
+688,604
| New | +$2.05M |
|
31
Mersana Therapeutics
MRSN
$34.8M
| $2.01M | 0.24% |
1,579,770
+1,529,770
| +3,060% | +$1.94M |
|
|
ALLK
32
DELISTED
Allakos
ALLK
| $1.79M | 0.21% |
787,056
+14,964
| +2% | +$34K |
|
33
Esperion Therapeutics
ESPR
$490M
| $1.7M | 0.2% |
1,737,636
+32,031
| +2% | +$31.4K |
|
34
Nuvation Bio
NUVB
$1.08B
| $1.64M | 0.2% |
+1,222,852
| New | +$1.64M |
|
35
Black Diamond Therapeutics
BDTX
$164M
| $1.59M | 0.19% |
555,572
+10,469
| +2% | +$30K |
|
36
BioVie
BIVI
$12.6M
| $1.56M | 0.19% |
457,345
+8,789
| +2% | +$29.7K |
|
|
CBAY
37
DELISTED
Cymabay Therapeutics
CBAY
| $1.56M | 0.19% |
+104,300
| New | +$1.56M |
|
38
AEON Biopharma
AEON
$9.43M
| $1.44M | 0.17% |
+257,977
| New | +$1.44M |
|
39
Milestone Pharmaceuticals
MIST
$151M
| $1.43M | 0.17% |
462,828
+2,412
| +0.5% | +$7.48K |
|
40
CRISPR Therapeutics
CRSP
$4.82B
| $1.39M | 0.17% |
+30,546
| New | +$1.39M |
|
41
KalVista Pharmaceuticals
KALV
$713M
| $1.37M | 0.17% |
142,692
+2,692
| +2% | +$25.9K |
|
42
Corbus Pharmaceuticals
CRBP
$121M
| $1.32M | 0.16% |
195,899
+3,639
| +2% | +$24.5K |
|
43
Acumen Pharmaceuticals
ABOS
$84.2M
| $1.31M | 0.16% |
315,265
-339,680
| -52% | -$1.41M |
|
44
VistaGen Therapeutics
VTGN
$113M
| $1.2M | 0.14% |
+229,100
| New | +$1.2M |
|
|
TECX
45
Tectonic Therapeutic, Inc. Common Stock
TECX
$305M
| $1.11M | 0.13% |
718,259
+584,113
| +435% | +$900K |
|
46
uniQure
QURE
$954M
| $1.06M | 0.13% |
+157,365
| New | +$1.06M |
|
47
Kezar Life Sciences
KZR
$28.5M
| $1.02M | 0.12% |
853,391
+11,795
| +1% | +$14K |
|
48
Terns Pharmaceuticals
TERN
$651M
| $832K | 0.1% |
165,480
-150,000
| -48% | -$755K |
|
49
Jasper Therapeutics
JSPR
$44.2M
| $788K | 0.09% |
1,125,087
| – | – |
|
|
ELEV
50
DELISTED
Elevation Oncology
ELEV
| $777K | 0.09% |
1,171,939
+22,449
| +2% | +$14.9K |
|